Karl-Erik Lundvall

Title: Karl-Erik Lundvall: Innovator in Pharmaceutical Chemistry

Introduction

Karl-Erik Lundvall is a notable inventor based in Ängelholm, Sweden. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds with immunomodulating activity. His work has led to the filing of multiple patents, showcasing his innovative approach to drug synthesis.

Latest Patents

Lundvall holds 2 patents, with his latest inventions focusing on two key areas. The first patent involves derivatives of quinoline-3-carboxanilide, which are compounds characterized by specific formulas where various groups are selected from hydrogen, hydroxy, and methoxy. These compounds exhibit immunomodulating activity, indicating their potential therapeutic applications. The second patent pertains to an improved method for synthesizing steroid esters. This method utilizes carbodiimides and catalytic amounts of 4-(tertiary amino)-pyridines, combined with acid catalysts, to produce pure, non-discolored compounds in high yields.

Career Highlights

Throughout his career, Lundvall has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Kabi Pharmacia and Ab Leo, where he contributed to various research and development projects. His expertise in pharmaceutical chemistry has been instrumental in advancing the synthesis of important compounds.

Collaborations

Lundvall has collaborated with several professionals in his field, including Kaj Johansson and Anders R Stamvik. These collaborations have fostered innovation and have been crucial in the development of his patented technologies.

Conclusion

Karl-Erik Lundvall's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as an influential inventor. His work continues to impact the field, paving the way for future advancements in drug development.